Boston Scientific Corporation (NYSE:BSX) Receives Average Rating of “Moderate Buy” from Analysts

Boston Scientific Corporation (NYSE:BSX) has received an average recommendation of “Moderate Buy” from the twenty-five research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $104.0455.

A number of brokerages have commented on BSX. Stifel Nicolaus reduced their target price on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, March 20th. National Bank Financial set a $115.00 price target on shares of Boston Scientific in a research note on Monday, February 2nd. Citigroup cut their price target on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday. UBS Group decreased their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Finally, Truist Financial lowered their price objective on Boston Scientific from $95.00 to $92.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.34% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BSX. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp increased its holdings in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. Financial Consulate Inc. purchased a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Finally, Swiss RE Ltd. purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE BSX opened at $61.83 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock’s fifty day moving average is $73.35 and its two-hundred day moving average is $88.76. The firm has a market capitalization of $91.89 billion, a P/E ratio of 31.87, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. Boston Scientific has a fifty-two week low of $60.90 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an “Outperform” after the CHAMPION‑AF readout met primary safety and efficacy endpoints — a clinical win that supports Boston Scientific’s electrophysiology franchise and long‑term revenue potential. Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout
• Positive Sentiment: Boston Scientific closed its acquisition of Valencia Technologies, strengthening its position against Medtronic in a currently under‑penetrated market — a strategic tuck‑in that could expand future addressable market and product offering. Boston Scientific closes buyout of Valencia Technologies
• Neutral Sentiment: Citigroup cut its price target from $94 to $87 but kept a “Buy” rating — this reduces near‑term upside from prior forecasts but maintains analyst conviction in BSX’s longer‑term thesis. Benzinga
• Negative Sentiment: Multiple securities‑fraud class action filings and numerous law‑firm shareholder alerts (Pomerantz, Gross, Bernstein Liebhard, Rosen, Levi & Korsinsky, Glancy Prongay Wolke, Faruqi & Faruqi, etc.) cite alleged disclosure issues covering July 23, 2025–Feb 3, 2026 and highlight a May 4, 2026 lead‑plaintiff deadline — increased litigation risk can pressure the stock via uncertainty and potential liability. Boston Scientific (BSX) Stock Sinks As Market Gains: Here’s Why Representative lawsuit coverage
• Negative Sentiment: Market commentary (e.g., Zacks) flagged today’s share decline relative to broader gains, suggesting selling pressure tied to the legal headlines and recent analyst adjustments. Boston Scientific (BSX) Stock Sinks As Market Gains: Here’s Why

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.